RENATA Stock Overview
Manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Renata PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ৳720.80 |
52 Week High | ৳1,217.90 |
52 Week Low | ৳608.30 |
Beta | 0.062 |
11 Month Change | -0.51% |
3 Month Change | -5.15% |
1 Year Change | -40.82% |
33 Year Change | -38.15% |
5 Year Change | -12.97% |
Change since IPO | 24,633.74% |
Recent News & Updates
Recent updates
Shareholder Returns
RENATA | BD Pharmaceuticals | BD Market | |
---|---|---|---|
7D | -2.6% | -0.5% | -0.5% |
1Y | -40.8% | -18.2% | -20.4% |
Return vs Industry: RENATA underperformed the BD Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: RENATA underperformed the BD Market which returned -21.5% over the past year.
Price Volatility
RENATA volatility | |
---|---|
RENATA Average Weekly Movement | 4.7% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 5.7% |
10% most volatile stocks in BD Market | 7.4% |
10% least volatile stocks in BD Market | 3.6% |
Stable Share Price: RENATA has not had significant price volatility in the past 3 months.
Volatility Over Time: RENATA's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | 7,119 | Syed S. Kabir | www.renata-ltd.com |
Renata PLC manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh. Its pharmaceutical products include antimicrobials, anti-hypertensive, anti-angina, anti-diabetic, eye-ear and topical preparation, antigout, NSAID, anti-spasmodic, steroid, anti-osteoporotic, anti-allergic, cardiovascular, CNS, hormone, anti-cancer, oxytocic, anti-fibrinolytic, anti-asthma, expectorant, oral rehydration saline, narcotic analgesic, antipyretic/analgesic, antiemetic, anesthetic, antiviral, and other products. The company also offers lipid lowering, antiulcer, anti-parasitic and anti-protozoal, anti-fungal, anti-tuberculosis, and gastroprokinetic agents; and vitamins and minerals, and amino acid supplements.
Renata PLC Fundamentals Summary
RENATA fundamental statistics | |
---|---|
Market cap | ৳82.67b |
Earnings (TTM) | ৳2.29b |
Revenue (TTM) | ৳36.47b |
36.0x
P/E Ratio2.3x
P/S RatioIs RENATA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RENATA income statement (TTM) | |
---|---|
Revenue | ৳36.47b |
Cost of Revenue | ৳22.25b |
Gross Profit | ৳14.22b |
Other Expenses | ৳11.92b |
Earnings | ৳2.29b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 20.00 |
Gross Margin | 38.99% |
Net Profit Margin | 6.29% |
Debt/Equity Ratio | 52.2% |
How did RENATA perform over the long term?
See historical performance and comparison